
tech
Moderna/Merck mRNA Vaccine Cuts Melanoma Risk by 42% — Phase 3 Trial Succeeds
A personalized mRNA cancer vaccine from Moderna and Merck has been shown to reduce the risk of death or recurrence from melanoma by 42% in a Phase 3 trial. The…
Alex Chen·3 min read·11h ago




